Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials

Joseph M. Caster; Artish N. Patel; Tian Zhang; Andrew Wang

doi:10.1002/wnan.1416

Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials

Joseph M. Caster, Artish N. Patel, Tian Zhang, Andrew Wang

Research output: Contribution to journal › Review article › peer-review

309 Scopus citations

Abstract

Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416. For further resources related to this article, please visit the WIREs website.

Original language	English (US)
Article number	e1416
Journal	Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1002/wnan.1416
State	Published - Jan 1 2017
Externally published	Yes

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering

Access to Document

10.1002/wnan.1416

Cite this

@article{bf04e2f60b264e6490568638e6677f23,

title = "Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials",

abstract = "Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416. For further resources related to this article, please visit the WIREs website.",

author = "Caster, {Joseph M.} and Patel, {Artish N.} and Tian Zhang and Andrew Wang",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2017",

month = jan,

day = "1",

doi = "10.1002/wnan.1416",

language = "English (US)",

volume = "9",

journal = "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology",

issn = "1939-5116",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Investigational nanomedicines in 2016

T2 - a review of nanotherapeutics currently undergoing clinical trials

AU - Caster, Joseph M.

AU - Patel, Artish N.

AU - Zhang, Tian

AU - Wang, Andrew

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416. For further resources related to this article, please visit the WIREs website.

AB - Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416. For further resources related to this article, please visit the WIREs website.

UR - http://www.scopus.com/inward/record.url?scp=84978374856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978374856&partnerID=8YFLogxK

U2 - 10.1002/wnan.1416

DO - 10.1002/wnan.1416

M3 - Review article

C2 - 27312983

AN - SCOPUS:84978374856

SN - 1939-5116

VL - 9

JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

IS - 1

M1 - e1416

ER -

Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this